论文部分内容阅读
目的评价诺和灵30R和二甲双胍联合治疗对已经口服降糖药但血糖控制不佳的2型糖尿病患者的有效性和安全性。方法选取2007年1月至2010年1月在本院住院的94例2型糖尿病患者,分别使用诺和灵30R(A组,54例)及诺和灵30R联合二甲双胍(B组,40例)治疗。治疗20周后评价两者的有效性和安全性。结果与基线相比,使用诺和灵30R及诺和灵30R联合二甲双胍治疗后,2组均能有效控制血糖,但诺和灵30R联合二甲双胍组,能有效减少胰岛素用量,血糖达标时间减少,减少低血糖发生,减轻体质量。治疗期间共发生轻度和重度低血糖事件各1例。结论诺和灵30R联合二甲双胍治疗可有效降低使用口服降糖药疗效不佳的2型糖尿病患者的糖化血红蛋白、空腹血糖、餐后2h血糖水平,有利于帮助和促进患者实现糖化血红蛋白达标。
Objective To evaluate the efficacy and safety of Novolin ® 30R combined with metformin in type 2 diabetes patients who have been given oral hypoglycemic agents but whose glycemic control is not well. Methods Ninety-four patients with type 2 diabetes mellitus admitted to our hospital from January 2007 to January 2010 were enrolled in this study. They were treated with Novolin 30R (group A, n = 54) and Novolin 30R with metformin (group B, n = 40) treatment. Efficacy and safety of both were evaluated after 20 weeks of treatment. Results Compared with baseline, norepinephra 30R and norepinephrine 30R combined with metformin treatment, 2 groups were able to effectively control blood glucose, but norepinephrine 30R combined with metformin group can effectively reduce the amount of insulin, reduce blood glucose compliance time and reduce Hypoglycemia occurs, reducing body weight. During the treatment of mild and severe hypoglycemia occurred in 1 case. CONCLUSION Novolin 30R combined with metformin can effectively reduce the HbAlc, fasting blood glucose and postprandial 2h blood glucose levels in patients with type 2 diabetes who are not effective in oral hypoglycemic agents, which is helpful to help and achieve compliance of patients with glycosylated hemoglobin.